Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 1/2015

01-01-2015 | Movement Disorders (M Okun, Section Editor)

An Update on the Use of Botulinum Toxin Therapy in Parkinson’s Disease

Authors: Reversa Mills, Laxman Bahroo, Fernando Pagan

Published in: Current Neurology and Neuroscience Reports | Issue 1/2015

Login to get access

Abstract

Botulinum toxin (BoNT) has gained widespread use in a variety of neurological conditions. Parkinson’s disease is a complex neurodegenerative disorder manifested by motor and non-motor symptoms that can cause significant disability. BoNT has been used to effectively treat a variety of symptoms related to Parkinson’s disease. This review will examine the current therapeutic indications of BoNT use in the following disorders related to Parkinson’s disease: cervical dystonia, blepharospasm and lid apraxia, focal hand dystonia, foot dystonia, laryngeal dystonia, oromandibular dystonia, camptocormia, hand and jaw tremor, sialorrhea, hyperhidrosis, dysphagia, constipation, and overactive bladder.
Literature
1.
Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson’s disease in the United States: economic burden of PD in the US. Mov Disord. 2013;28:311–8.PubMedCrossRef
2.
Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24:1641–9.PubMedCrossRef
3.
Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P. Parkinson’s disease: the non-motor issues. Parkinsonism Relat Disord. 2011;17:717–23.PubMedCrossRef
4.
Diamond A, Jankovic J. Treatment of advanced Parkinson’s disease. Expert Rev Neurother. 2006;6:1181–97.PubMedCrossRef
5.
6.
Sheffield JK, Jankovic J. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson’s disease. Expert Rev Neurother. 2007;7:637–47.PubMedCrossRef
7.••
Hallett M, Albanese A, Dressler D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;67:94–114. This review provided recommendations for the therapeutic use of botulinum toxin based on various levels of evidence of available clinical studies supporting the efficacy and safety of each indication. Botulinum toxins were evaluated by the serotype A and B and also each formulation was studied individually. Recommendations based on the level of clinical evidence were presented for the treatment of various movement disorders including blepharospasm, hemifacial spasm, oromandibular dystonia, cervical dystonia, limb dystonia, laryngeal dystonia, tics and essential tremor.PubMedCrossRef
8.
Simpson DM, Blitzer A, Brashear A, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1699–706.PubMedCrossRef
9.
Naumann M, Dressler D, Hallett M, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon Off J Int Soc Toxinology. 2013;67:141–52.CrossRef
10.
Naumann M, So Y, Argoff CE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1707–14.PubMedCrossRef
11.
Lacy BE, Weiser K, Kennedy A. Botulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future? Gastroenterol Hepatol. 2008;4:283.
12.
Charles D, Gill CE. Neurotoxin injection for movement disorders. Contin Minneap Minn. 2010;16:131–57.
13.•
Truong D. Botulinum toxins in the treatment of primary focal dystonias. J Neurol Sci. 2012;316:9–14. This article reviews each formulation of Botulinum toxin type A and B for the treatment of various forms of focal dystonia. Clinical trials are presented comparing the safety, efficacy and duration of effect of the various formulations of botulinum toxin. Botulinum toxin therapy is considered to be first line therapy for the treatment of focal dystonia.PubMedCrossRef
14.
Albanese A et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord Off J Mov Disord Soc. 2013;28:863–73.CrossRef
15.•
Thenganatt MA, Jankovic J. Treatment of dystonia. Neurotherapeutics. 2014;11:139–52. This review details the various treatment options for dystonia including oral medications, botulinum toxin, surgical procedures including Deep Brain stimulation, physical and other types of therapies. Clinical trials of botulinum toxin in the treatment of various forms of dystonia are presented with varying levels of supporting evidence. This article concluded that a combination of therapies is most effective in the treatment of dystonia.PubMedCentralPubMedCrossRef
16.
17.
Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson’s disease. CNS Drugs. 2007;21:677–92.PubMedCrossRef
18.
Hallett M, Benecke R, Blitzer A, Comella CL. Treatment of focal dystonias with botulinum neurotoxin. Toxicon. 2009;54:628–33.PubMedCrossRef
19.
Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord Off J Mov Disord Soc. 1991;6:119–26.CrossRef
20.
Tolosa E, Compta Y. Dystonia in Parkinson’s disease. J Neurol. 2006;253 Suppl 7:VII7–13.PubMed
21.
Ashour R, Tintner R, Jankovic J. Striatal deformities of the hand and foot in Parkinson’s disease. Lancet Neurol. 2005;4:423–31.PubMedCrossRef
22.
Kruisdijk JJM, Koelman JHTM, OngerboerdeVisser BW, de Haan RJ, Speelman JD. Botulinum toxin for writer’s cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry. 2007;78:264–70.PubMedCentralPubMedCrossRef
23.
Contarino MF, Kruisdijk JJM, Koster L, et al. Sensory integration in writer’s cramp: comparison with controls and evaluation of botulinum toxin effect. Clin Neurophysiol Off J Int Fed Clin Neurophysiol. 2007;118:2195–206.CrossRef
24.
Tsui JK, Bhatt M, Calne S, Calne DB. Botulinum toxin in the treatment of writer’s cramp: a double-blind study. Neurology. 1993;43:183–5.PubMedCrossRef
25.
Yoshimura DM, Aminoff MJ, Olney RK. Botulinum toxin therapy for limb dystonias. Neurology. 1992;42:627–30.PubMedCrossRef
26.
Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord Off J Mov Disord Soc. 2005;20 Suppl 11:S11–16.CrossRef
27.
Pacchetti C, Albani G, Martignoni E, et al. ‘Off’ painful dystonia in Parkinson’s disease treated with botulinum toxin. Mov Disord Off J Mov Disord Soc. 1995;10:333–6.CrossRef
28.
Troung DD, Rontal M, Rolnick M, Aronson AE, Mistura K. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope. 1991;101:630–4.PubMed
29.
Adams SG, Hunt EJ, Irish JC, et al. Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia. J Otolaryngol. 1995;24:345–51.PubMed
30.
Finnegan EM, Luschei ES, Gordon JD, Barkmeier JM, Hoffman HT. Increased stability of airflow following botulinum toxin injection. Laryngoscope. 1999;109:1300–6.PubMedCrossRef
31.
Ludlow CL, Naunton RF, Sedory SE, Schulz GM, Hallett M. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology. 1988;38:1220–5.PubMedCrossRef
32.
Wong DL, Adams SG, Irish JC, et al. Effect of neuromuscular activity on the response to botulinum toxin injections in spasmodic dysphonia. J Otolaryngol. 1995;24:209–16.PubMed
33.
Adler CH, Bansberg SF, Krein-Jones K, Hentz JG. Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia. Mov Disord Off J Mov Disord Soc. 2004;19:1075–9.CrossRef
34.
Sinclair CF, Gurey LE, Blitzer A. Oromandibular dystonia: long-term management with botulinum toxin: management of OMD with botulinum toxin. Laryngoscope. 2013;123:3078–83.PubMedCrossRef
35.
Lee KH. Oromandibular dystonia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:491–6.PubMedCrossRef
36.
Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology. 1987;37:616–23.PubMedCrossRef
37.
Lee SJ, McCall WD, Kim YK, Chung SC, Chung JW. Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial. Am J Phys Med Rehabil Assoc Acad Physiatr. 2010;89:16–23.CrossRef
38.
Peeraully T, Tan E-K. Camptocormia in Parkinson’s disease: dystonia or myopathy? Basal Ganglia. 2012;2:1–3.CrossRef
39.
Azher SN, Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology. 2005;65:355–9.PubMedCrossRef
40.
Rahimi F, Bee C, Debicki D, et al. Effectiveness of BoNT A in Parkinson’s disease upper limb tremor management. Can J Neurol Sci. 2013;40:663–9.PubMedCrossRef
41.
42.
Pullman SL, Greene P, Fahn S, Pedersen SF. Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. Arch Neurol. 1996;53:617–24.PubMedCrossRef
43.
Trosch RM, Pullman SL. Botulinum toxin A injections for the treatment of hand tremors. Mov Disord Off J Mov Disord Soc. 1994;9:601–9.CrossRef
44.
Henderson JM, Ghika JA, Van Melle G, Haller E, Einstein R. Botulinum toxin A in non-dystonic tremors. Eur Neurol. 1996;36:29–35.PubMedCrossRef
45.
Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord Off J Mov Disord Soc. 1996;11:250–6.CrossRef
46.
Brin MF, Lyons KE, Doucette J, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001;56:1523–8.PubMedCrossRef
47.
Schneider SA, Edwards MJ, Cordivari C, Macleod WN, Bhatia KP. Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson’s disease. Mov Disord Off J Mov Disord Soc. 2006;21:1722–4.CrossRef
48.
Meningaud J-P, Pitak-Arnnop P, Chikhani L, Bertrand J-C. Drooling of saliva: a review of the etiology and management options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:48–57.PubMedCrossRef
49.
Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368–76.PubMedCrossRef
50.
Pinnington LL, Muhiddin KA, Ellis RE, Playford ED. Non-invasive assessment of swallowing and respiration in Parkinson’s disease. J Neurol. 2000;247:773–7.PubMedCrossRef
51.
Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Long-lasting benefits of botulinum toxin type B in Parkinson’s disease-related drooling. J Neurol. 2009;256:563–7.PubMedCrossRef
52.
Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology. 2003;61:1279–81.PubMedCrossRef
53.
Mancini F, Zangaglia R, Cristina S, et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord Off J Mov Disord Soc. 2003;18:685–8.CrossRef
54.
Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord Off J Mov Disord Soc. 2006;21:704–7.CrossRef
55.
Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology. 2004;62:37–40.PubMedCrossRef
56.
Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology. 2005;65:765–7.PubMedCrossRef
57.
Dogu O, Apaydin D, Sevim S, Talas DU, Aral M. Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease. Clin Neurol Neurosurg. 2004;106:93–6.PubMedCrossRef
58.
Swinn L, Schrag A, Viswanathan R, et al. Sweating dysfunction in Parkinson’s disease. Mov Disord Off J Mov Disord Soc. 2003;18:1459–63.CrossRef
59.
Murray CA, Cohen JL, Solish N. Treatment of focal hyperhidrosis. J Cutan Med Surg. 2007;11:67–77.PubMed
60.
Bushmann M, Dobmeyer SM, Leeker L, Perlmutter JS. Swallowing abnormalities and their response to treatment in Parkinson’s disease. Neurology. 1989;39:1309–14.PubMedCrossRef
61.
Bird MR, Woodward MC, Gibson EM, Phyland DJ, Fonda D. Asymptomatic swallowing disorders in elderly patients with Parkinson’s disease: a description of findings on clinical examination and videofluoroscopy in sixteen patients. Age Ageing. 1994;23:251–4.PubMedCrossRef
62.
Mari F, Matei M, Ceravolo MG, et al. Predictive value of clinical indices in detecting aspiration in patients with neurological disorders. J Neurol Neurosurg Psychiatry. 1997;63:456–60.PubMedCentralPubMedCrossRef
63.
Gui D, Rossi S, Runfola M, Magalini SC. Botulinum toxin in the therapy of gastrointestinal motility disorders. Aliment Pharmacol Ther. 2003;18:1–16.PubMedCrossRef
64.
Pasricha PJ, Rai R, Ravich WJ, Hendrix TR, Kalloo AN. Botulinum toxin for achalasia: long-term outcome and predictors of response. Gastroenterology. 1996;110:1410–5.PubMedCrossRef
65.
Neubrand M, Scheurlen C, Schepke M, Sauerbruch T. Long-term results and prognostic factors in the treatment of achalasia with botulinum toxin. Endoscopy. 2002;34:519–23.PubMedCrossRef
66.
Mikaeli J, Fazel A, Montazeri G, Yaghoobi M, Malekzadeh R. Randomized controlled trial comparing botulinum toxin injection to pneumatic dilatation for the treatment of achalasia. Aliment Pharmacol Ther. 2001;15:1389–96.PubMedCrossRef
67.
D’Onofrio V, Miletto P, Leandro G, Iaquinto G. Long-term follow-up of achalasia patients treated with botulinum toxin. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2002;34:105–10.
68.
Ghoshal UC, Chaudhuri S, Pal BB, et al. Randomized controlled trial of intrasphincteric botulinum toxin A injection versus balloon dilatation in treatment of achalasia cardia. Dis Esophagus Off J Int Soc Dis Esophagus ISDE. 2001;14:227–31.CrossRef
69.
Annese V, Bassotti G, Coccia G, et al. A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. GISMAD Achalasia Study Group. Gut. 2000;46:597–600.PubMedCentralPubMedCrossRef
70.
Brisinda G, Bentivoglio AR, Maria G, Albanese A. Treatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms. Mov Disord. 2004;19:S146–56.PubMedCrossRef
71.
Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Parkinsonism Relat Disord. 2011;17:10–5.PubMedCrossRef
72.
Mathers SE, Kempster PA, Swash M, Lees AJ. Constipation and paradoxical puborectalis contraction in anismus and Parkinson’s disease: a dystonic phenomenon? J Neurol Neurosurg Psychiatry. 1988;51:1503–7.PubMedCentralPubMedCrossRef
73.
Albanese A, Brisinda G, Bentivoglio AR, Maria G. Treatment of outlet obstruction constipation in Parkinson’s disease with botulinum neurotoxin A. Am J Gastroenterol. 2003;98:1439–40.PubMedCrossRef
74.
Cadeddu F, Bentivoglio AR, Brandara F, et al. Outlet type constipation in Parkinson’s disease: results of botulinum toxin treatment. Aliment Pharmacol Ther. 2005;22:997–1003.PubMedCrossRef
75.
Sakakibara R, Tateno F, Nagao T, et al. Bladder function of patients with Parkinson’s disease: bladder function of patients with PD. Int J Urol. 2014;21:638–46.PubMedCrossRef
76.
Sakakibara R, Shinotoh H, Uchiyama T, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease. Auton Neurosci Basic Clin. 2001;92:76–85.CrossRef
77.
Giannantoni A, Rossi A, Mearini E, et al. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson’s disease and multiple system atrophy. J Urol. 2009;182:1453–7.PubMedCrossRef
78.
Giannantoni A, Conte A, Proietti S, et al. Botulinum toxin type A in patients with Parkinson’s disease and refractory overactive bladder. J Urol. 2011;186:960–4.PubMedCrossRef
79.
Kulaksizoglu H, Parman Y. Use of botulinum toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons’s disease. Parkinsonism Relat Disord. 2010;16:531–4.PubMedCrossRef
80.
81.
Baizabal-Carvallo JF, Jankovic J, Pappert E. Flu-like symptoms following botulinum toxin therapy. Toxicon Off J Int Soc Toxinology. 2011;58:1–7.CrossRef
82.
Baizabal-Carvallo JF, Jankovic J, Feld J. Flu-like symptoms and associated immunological response following therapy with botulinum toxins. Neurotox Res. 2013;24:298–306.PubMedCrossRef
83.
Metadata
Title
An Update on the Use of Botulinum Toxin Therapy in Parkinson’s Disease
Authors
Reversa Mills
Laxman Bahroo
Fernando Pagan
Publication date
01-01-2015
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 1/2015
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-014-0511-3

Other articles of this Issue 1/2015

Current Neurology and Neuroscience Reports 1/2015 Go to the issue

Stroke (HP Adams, Section Editor)

Nanotheragnostic Applications for Ischemic and Hemorrhagic Strokes: Improved Delivery for a Better Prognosis

Sleep (M Thorpy, M Billiard, Section Editors)

Cataplexy and Sleep Disorders in Niemann-Pick Type C Disease

Neuro-Oncology (LE Abrey, Section Editor)

Treatment Considerations for MGMT-Unmethylated Glioblastoma

Neuro-Oncology (LE Abrey, Section Editor)

Vaccine Therapies in Malignant Glioma

Stroke (HP Adams, Section Editor)

Sleep Apnea and Stroke

Neuro-Oncology (LE Abrey, Section Editor)

Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and Correlation with Molecular Characteristics